Sudan Loganathan
Stock Analyst at Stephens
(4.34)
# 1,320
Out of 4,676 analysts
35
Total ratings
64.7%
Success rate
26.9%
Average return
Main Sectors:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics | Rated: Buy | $8 → $5 | $1.04 | +380.77% | 3 | Jun 4, 2026 | |
| PVLA Palvella Therapeutics | Initiated Coverage: Buy | $220 | $148.24 | +48.41% | 1 | May 11, 2026 | |
| IMNM Immunome | Rated: Buy | $33 → $30 | $29.39 | +2.09% | 3 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $110 → $100 | $126.64 | -21.04% | 3 | Mar 2, 2026 | |
| ARVN Arvinas | Maintained: Buy | $15 → $18 | $9.60 | +87.50% | 4 | Feb 25, 2026 | |
| APGE Apogee Therapeutics | Initiated Coverage: Buy | $95 | $134.85 | -29.55% | 1 | Dec 17, 2025 | |
| PYXS Pyxis Oncology | Maintained: Buy | $13 → $8 | $3.06 | +161.44% | 2 | Nov 24, 2025 | |
| CADL Candel Therapeutics | Initiated Coverage: Buy | $15 | $13.60 | +10.29% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Upgraded: Buy | $4 → $6 | $4.20 | +42.86% | 2 | Sep 15, 2025 | |
| FTH Faeth Therapeutics | Maintained: Buy | $5 → $35 | $34.52 | n/a | 2 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $29 → $60 | $56.72 | n/a | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $30 | $26.95 | n/a | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $5 | $1.08 | n/a | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $11.71 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $42.48 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $25 | $4.39 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 | $16.92 | n/a | 1 | May 13, 2024 |
ADC Therapeutics
Jun 4, 2026
Rated: Buy
Price Target: $8 → $5
Current: $1.04
Upside: +380.77%
Palvella Therapeutics
May 11, 2026
Initiated Coverage: Buy
Price Target: $220
Current: $148.24
Upside: +48.41%
Immunome
Mar 4, 2026
Rated: Buy
Price Target: $33 → $30
Current: $29.39
Upside: +2.09%
Kymera Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: $110 → $100
Current: $126.64
Upside: -21.04%
Arvinas
Feb 25, 2026
Maintained: Buy
Price Target: $15 → $18
Current: $9.60
Upside: +87.50%
Apogee Therapeutics
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $95
Current: $134.85
Upside: -29.55%
Pyxis Oncology
Nov 24, 2025
Maintained: Buy
Price Target: $13 → $8
Current: $3.06
Upside: +161.44%
Candel Therapeutics
Oct 28, 2025
Initiated Coverage: Buy
Price Target: $15
Current: $13.60
Upside: +10.29%
C4 Therapeutics
Sep 15, 2025
Upgraded: Buy
Price Target: $4 → $6
Current: $4.20
Upside: +42.86%
Faeth Therapeutics
Jun 30, 2025
Maintained: Buy
Price Target: $5 → $35
Current: $34.52
Upside: n/a
Jun 24, 2025
Upgraded: Buy
Price Target: $29 → $60
Current: $56.72
Upside: n/a
Apr 9, 2025
Maintained: Buy
Price Target: $20 → $30
Current: $26.95
Upside: n/a
Nov 19, 2024
Reiterated: Buy
Price Target: $25 → $5
Current: $1.08
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $15
Current: $11.71
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $42.48
Upside: n/a
Nov 7, 2024
Initiated Coverage: Hold
Price Target: $25
Current: $4.39
Upside: n/a
May 13, 2024
Rated: Buy
Price Target: $25
Current: $16.92
Upside: n/a